Skip to main content
OpenTrials
Completed

NCT Number: NCT04460027

W-SUDs for COVID-19

The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic.

This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Stanford University

Palo Alto, California, 94306, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All genders aged 18-65 years
  • Access to a smartphone
  • Available and committed to engage with app and complete assessments
  • Be willing to provide email address (as this is how assessment incentives will be distributed),
  • Literate in English (as W-SUDs conversational and video materials will be in English).

Exclusion criteria

  • Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population)
  • History of severe drug/alcohol use
  • History of opioid misuse without medication-assisted treatment
  • Suicide attempt within the past year
  • Opioid overdose within the past year

Treatment and study plan

Woebot Substance Use Disorder

Other

Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.

Primary outcomes

  1. Change in Number of Substance Use Occasions in the Past 30 Days From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Change in number of substance use occasions in the past 30 days from Baseline to Post-treatment at 8 weeks

Secondary outcomes

  1. Change in Short Inventory of Problems - Alcohol and Drugs (SIP-AD) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Measure of substance use problems. The SIP-AD assesses substance use problems in the past 30 days. Total score consists of of the sum of all 15 items, ranging from 0-45, where greater scores indicate greater substance use problems.

  2. Change in Drug Abuse Screening Test (DAST-10) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Measure of drug abuse related consequences. The DAST-10 is a brief, 10-item self-report measure that assesses consequences related to drug abuse, excluding alcohol and tobacco. The range is 0-10, where higher scores indicate greater severity. Adapted from past 12 months to past 30 days.

  3. Change in Brief Situational Confidence Questionnaire (BSCQ) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% ("not at all confident") and 100% ("totally confident") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence.

  4. Change in Craving Ratings From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    A one-item, self-reported rating of craving intensity to use substances over the past 7 days. Score ranges is from 0-4, where a greater score indicates a more intense urge to use.

  5. Change in Pain Ratings From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 Weeks

    A one item, self-reported rating of pain. Scores range from 0-100 where higher scores indicate greater levels of pain.

  6. Change in Patient Health Questionnaire-8 (PHQ-8) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Measure of depression. An 8-item self-report questionnaire that assesses the frequency and severity of depression symptoms. Total scores range from 0 to 24 where higher scores indicate greater levels of depression.

  7. Change in General Anxiety Disorder (GAD-7) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Measure of anxiety. A 7-item brief self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Total score between 0-21, where higher scores indicate greater levels of anxiety.

  8. Change in CAIR Pandemic Impact Questionnaire (CAIR-PIQ) From Baseline to Post-treatment at 8 Weeks

    Time frame: Change from Baseline to Post-treatment at 8 weeks

    Assesses impact of the COVID-19 pandemic in terms of exposure to stressors, mental health impact, and growth. Possible total score range from 0-22, where greater scores are related to greater impact.

  9. Client Satisfaction Questionnaire (CSQ) at Post-treatment at 8 Weeks

    Time frame: Post-treatment (8 weeks from Baseline)

    Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, "How would you rate the quality of service you received"? and "Did you get the kind of service you wanted?" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application.

  10. Usage Rating Profile - Intervention (URPI)-Acceptability at Post-treatment at 8 Weeks

    Time frame: Post-treatment (8 weeks from Baseline)

    Measure of acceptability. A 6-item subscale that inquires about intervention acceptability. Total scores range from 6-36, where greater scores indicate greater intervention acceptability.

  11. Usage Rating Profile - Intervention (URPI)-Feasibility at Post-treatment at 8 Weeks

    Time frame: Post-treatment (8 weeks from Baseline)

    Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Total scores range from 6-36, where greater scores indicate greater intervention feasibility.

  12. Change in Working Alliance Inventory (WAI-SR) From Mid-treatment at 4 Weeks to Post-treatment at 8 Weeks

    Time frame: Change from Mid-treatment at 4 weeks to Post-treatment at 8 weeks

    Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Total scores range from 12-60, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing "therapist" with "Woebot".

Sponsors and collaborators

Lead sponsor

Woebot Health

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • Stanford University

Registry information

Official study title

Woebot for Substance Use Disorders During COVID-19

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 7, 2020
Registry last updated
Dec 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.